Stifel Nicolaus reiterated their hold rating on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a research report sent to investors on Monday morning, AnalystRatings.com reports. They currently have a $86.00 target price on the biopharmaceutical company’s stock.
“We are reiterating our Hold rating on ICPT after the company reported a slight 2Q19 beat on Ocaliva revenues, which appear to have been aided by a benefit in channel inventories. With that said, our thesis remains unchanged and we think there are too many unknown variables in terms of OCA’s potential adcom/approval and launch in NASH for us to be comfortable recommending the stock here. Management remains on track to file its NDA for OCA in NASH by the end of this quarter followed by its MAA filing in the EU in 4Q19. We think investor focus remains on the potential for OCA in NASH and in particular: whether or not ICPT’s filing of a NDA for OCA in NASH (rather than a sNDA) can lead to bi- furcated/indication based pricing, potential payer/reimbursement dynamics in the NASH category and the use of non-invasive biomarkers vs. biopsy for diagnosis.”,” the firm’s analyst wrote.
Several other equities analysts have also recently weighed in on the company. Cowen reiterated a buy rating and issued a $149.00 price target on shares of Intercept Pharmaceuticals in a research report on Wednesday, May 8th. ValuEngine upgraded Intercept Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, August 1st. Wells Fargo & Co upgraded Intercept Pharmaceuticals from a market perform rating to an outperform rating and set a $90.02 price target for the company in a research report on Thursday, May 2nd. Raymond James set a $149.00 price target on Intercept Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, August 7th. Finally, Zacks Investment Research upgraded Intercept Pharmaceuticals from a sell rating to a hold rating and set a $73.00 price target for the company in a research report on Monday, July 15th. Three analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have issued a buy rating to the company’s stock. Intercept Pharmaceuticals presently has a consensus rating of Buy and an average target price of $138.86.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($2.28) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.51) by $0.23. The firm had revenue of $66.30 million for the quarter, compared to analyst estimates of $58.78 million. Intercept Pharmaceuticals had a negative return on equity of 1,572.61% and a negative net margin of 143.57%. The business’s revenue was up 52.2% on a year-over-year basis. During the same period in the previous year, the company posted ($2.58) earnings per share. Sell-side analysts anticipate that Intercept Pharmaceuticals will post -10.07 earnings per share for the current fiscal year.
In related news, insider Lisa Bright sold 595 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $78.66, for a total transaction of $46,802.70. Following the completion of the transaction, the insider now directly owns 20,452 shares in the company, valued at $1,608,754.32. The transaction was disclosed in a document filed with the SEC, which is available through this link. 5.00% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of ICPT. Squarepoint Ops LLC lifted its stake in shares of Intercept Pharmaceuticals by 3.6% in the 4th quarter. Squarepoint Ops LLC now owns 3,399 shares of the biopharmaceutical company’s stock valued at $343,000 after acquiring an additional 118 shares during the last quarter. Hanseatic Management Services Inc. raised its position in Intercept Pharmaceuticals by 12.1% during the 1st quarter. Hanseatic Management Services Inc. now owns 2,077 shares of the biopharmaceutical company’s stock valued at $232,000 after purchasing an additional 224 shares during the last quarter. Profund Advisors LLC raised its position in Intercept Pharmaceuticals by 4.7% during the 2nd quarter. Profund Advisors LLC now owns 6,399 shares of the biopharmaceutical company’s stock valued at $509,000 after purchasing an additional 285 shares during the last quarter. Financial Gravity Wealth Inc. bought a new position in Intercept Pharmaceuticals during the 1st quarter valued at approximately $33,000. Finally, Prudential Financial Inc. raised its position in Intercept Pharmaceuticals by 14.2% during the 2nd quarter. Prudential Financial Inc. now owns 2,660 shares of the biopharmaceutical company’s stock valued at $212,000 after purchasing an additional 330 shares during the last quarter. Hedge funds and other institutional investors own 77.24% of the company’s stock.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
See Also: Debt-To-Equity Ratio
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.